• The Hearing Panel of the Patented Medicine Prices Review Board has made public its decision in the matter of Alexion Pharmaceuticals Inc. and the medicine Soliris. The Panel orders Alexion to:
  • pay to Her Majesty in right of Canada an amount calculated by the parties in accordance with Schedule A of the Decision (to be approved by the Panel); and
  • lower the list price of Soliris in Canada as of the date of the Decision to no higher than the lowest price in the seven comparator countries set out in the current Patented Medicines Regulations.

The Decision – Board Order can be found on the PMPRB’s website.